Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.76 USD | -0.56% | +4.03% | +53.36% |
31/05 | Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 | MT |
31/05 | Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment | MT |
- Stock Market
- Equities
- CALTX Stock
- CALT Stock
- News Calliditas Therapeutics AB
- MarketScreener Strategies